Related Experiment Video
Updated: Feb 23, 2026

Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples
Published on: April 21, 2014
Septal alcoholization in hypertrophic cardiomyopathy: about 11 cases
Yibar Kambiré1,2, Georges Rosario Christian Millogo2,3, Claire Dauphin4
1Department of Medicine and Specialties, National Hospital Blaise Compaoré, Ouagadougou, Burkina Faso.
Insights
Septal alcoholization effectively reduced left ventricular outflow tract obstruction in hypertrophic obstructive cardiomyopathy patients. This procedure showed an 81.8% success rate, improving symptoms and quality of life.
Area of Science:
- Cardiology
- Interventional Cardiology
- Cardiac Surgery
Background:
- Hypertrophic obstructive cardiomyopathy (HOCM) outcomes after septal alcoholization require further study.
- Limited data exists on septal alcoholization effectiveness across various medical centers.
Purpose of the Study:
- To evaluate the outcomes of septal alcoholization in patients with hypertrophic obstructive cardiomyopathy.
- To assess the efficacy and safety of alcohol septal ablation in a single-center cohort.
Main Methods:
- Retrospective and prospective descriptive study of 11 HOCM patients (≥18 years) undergoing alcohol septal ablation.
- Inclusion criteria: HOCM with left ventricular outflow tract obstruction ≥ 50 mmHg, symptomatic despite medical therapy.
- Data collected via medical records and patient/physician interviews; analyzed using EPI info 6.04.
Main Results:
- Successful reduction in left ventricular outflow tract obstruction from 98.18 mmHg to 18.91 mmHg over 25.64 months.
- Overall success rate of 81.8%; common indications included dyspnea (45.5%) and lipothymia (18.2%).
- Significant incidence of conductive disorders (45.5%), necessitating pacemakers (36.4%) and defibrillators (27.3%).
Conclusions:
- Septal alcoholization is a successful treatment for hypertrophic obstructive cardiomyopathy, significantly reducing obstruction and improving symptoms.
- While effective, careful monitoring for and management of conductive disorders post-ablation are crucial.
- Further research is warranted to optimize patient selection and management strategies for alcohol septal ablation.
Abstract:
Outcomes of septal alcoholization in hypertrophic obstructive cardiomyopathy are not enough studied in all centers. The purpose of this study was to determine the outcomes of septal alcoholization in hypertrophic obstructive cardiomyopathy in our hospital. A retrospective and prospective descriptive study focused on all patients aged at least 18 years treated by alcohol septal ablation between July 2005 and June 2010 in the cardiology unit of Clermont-Ferrand teaching Hospital. The inclusion criteria were, hypertrophic obstructive cardiomyopathy with left ventricular outflow tract obstruction ≥ 50 mmHg, symptomatic despite optimal medical therapy. The clinical, paraclinical data and the results of alcohol ablation were collected from medical records of patients and a telephone conversation with the patients or their physicians. These data were analyzed by EPI info 6.04. Eleven patients with average age of 56.27 ± 15, 83 were included of which 81.8% of men. The main indications of alcohol septal were dyspnea stage NYHA II-IV (45.5%), lipothymia (18.2%) and invalidating angina (18.2%). Main electrocardiographic abnormalities were left ventricular hypertrophy and disorders of repolarization with 72.7% each. Minor conductive disorders were found in 45.5% of the cases. The left ventricular outflow tract obstruction was 98.18 ± 25.93 mmHg before alcohol septal ablation and 18.91 ± 31.97 mmHg after a follow-up of 25.64 ± 21.97 months. The success rate was 81.8%. Conductive disorders (45.5%) required the establishment of a definitive pacemaker in 36.4% of the patients. A cardiac defibrillator was implanted at 27.3%. Septal alcoholization was succesful.
More Related Videos
03:45Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
08:31Isolation of Atrial Cardiomyocytes from a Rat Model of Metabolic Syndrome-related Heart Failure with Preserved Ejection Fraction
Published on: July 26, 2018
Related Concept Videos
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy IV: Restrictive Cardiomyopathy
Cardiomyopathy VII: Pre and Post Operative Nursing Management